These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 22525297

  • 1. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
    Dariusz S, Agnieszka M, Elzbieta R, Danuta ON, Maciej Z, Piotr D, Nowicki M.
    Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):193-9. PubMed ID: 22525297
    [Abstract] [Full Text] [Related]

  • 2. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 3. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 6. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 7. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, Bauer A, Petry IB, Koelbl H, Hengstler JG.
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 11. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ, Krikun G, Papp C, Aigner S, Schatz F.
    J Clin Endocrinol Metab; 1995 Apr 01; 80(4):1100-5. PubMed ID: 7714076
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ.
    J Pathol; 2002 Sep 01; 198(1):92-9. PubMed ID: 12210068
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M, Babić D, Abramić M, Milicić D, Vrhovec I, Skrk J.
    Neoplasma; 2001 Sep 01; 48(6):462-7. PubMed ID: 11949838
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M.
    Urol Oncol; 2009 Sep 01; 27(2):180-6. PubMed ID: 18439850
    [Abstract] [Full Text] [Related]

  • 19. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.